IL295724A - Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids - Google Patents
Compositions and methods for organ-protective expression and modulation of coding ribonucleic acidsInfo
- Publication number
- IL295724A IL295724A IL295724A IL29572422A IL295724A IL 295724 A IL295724 A IL 295724A IL 295724 A IL295724 A IL 295724A IL 29572422 A IL29572422 A IL 29572422A IL 295724 A IL295724 A IL 295724A
- Authority
- IL
- Israel
- Prior art keywords
- mirna
- mrna construct
- orf
- sequence
- mrna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979619P | 2020-02-21 | 2020-02-21 | |
| US202063059458P | 2020-07-31 | 2020-07-31 | |
| PCT/US2021/019028 WO2021168405A1 (en) | 2020-02-21 | 2021-02-22 | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295724A true IL295724A (en) | 2022-10-01 |
Family
ID=77391786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295724A IL295724A (en) | 2020-02-21 | 2021-02-22 | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11596685B2 (https=) |
| EP (1) | EP4106770A4 (https=) |
| JP (1) | JP7539723B2 (https=) |
| KR (2) | KR102838785B1 (https=) |
| CN (1) | CN115297868B (https=) |
| AU (2) | AU2021224990B2 (https=) |
| CA (1) | CA3168048A1 (https=) |
| IL (1) | IL295724A (https=) |
| MX (1) | MX2022010084A (https=) |
| WO (1) | WO2021168405A1 (https=) |
| ZA (1) | ZA202208795B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714430D0 (en) * | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP4065600A1 (en) | 2019-11-25 | 2022-10-05 | Cornell University | Apoe gene therapy |
| CN113583977B (zh) * | 2020-04-30 | 2025-06-06 | 杭州康万达医药科技有限公司 | 可受微小rna调控的分离的重组溶瘤痘病毒及其应用 |
| MX2023001187A (es) * | 2020-07-31 | 2023-04-04 | Combined Therapeutics Inc | Composiciones y métodos para una vacunación mejorada. |
| CN116445492A (zh) * | 2022-01-10 | 2023-07-18 | 北京锦篮基因科技有限公司 | 用于x染色体连锁肾上腺脑白质营养不良的基因治疗药物和方法 |
| CN114874999B (zh) * | 2022-04-22 | 2023-04-21 | 中国医学科学院病原生物学研究所 | 一种基于痘苗病毒载体的新型冠状病毒病毒样颗粒疫苗 |
| CN116004628B (zh) * | 2023-01-03 | 2024-07-19 | 苏州大学 | 一种预防或治疗慢性疼痛的miRNA靶点及其应用 |
| CN117530932B (zh) * | 2024-01-08 | 2024-04-26 | 中国药科大学 | 一种抑制肿瘤生长及肺转移的人工外泌体及其应用 |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| US7993831B2 (en) * | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
| WO2010126766A1 (en) * | 2009-04-30 | 2010-11-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| SI3458083T1 (sl) * | 2016-05-18 | 2023-03-31 | Modernatx, Inc. | Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba |
| CN110402145A (zh) * | 2016-10-26 | 2019-11-01 | 莫得纳特斯公司 | 用于增强免疫应答的信使核糖核酸及其使用方法 |
| WO2018115527A2 (en) * | 2016-12-23 | 2018-06-28 | Curevac Ag | Mers coronavirus vaccine |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP4008333A1 (en) * | 2018-02-19 | 2022-06-08 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| EP3986447A4 (en) * | 2019-06-18 | 2023-08-16 | Citranvi Biosciences, LLC | RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES |
| GB2594683A (en) * | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
-
2021
- 2021-02-22 JP JP2022549303A patent/JP7539723B2/ja active Active
- 2021-02-22 WO PCT/US2021/019028 patent/WO2021168405A1/en not_active Ceased
- 2021-02-22 AU AU2021224990A patent/AU2021224990B2/en active Active
- 2021-02-22 MX MX2022010084A patent/MX2022010084A/es unknown
- 2021-02-22 EP EP21757897.0A patent/EP4106770A4/en active Pending
- 2021-02-22 KR KR1020227031791A patent/KR102838785B1/ko active Active
- 2021-02-22 KR KR1020257024617A patent/KR20250114450A/ko active Pending
- 2021-02-22 IL IL295724A patent/IL295724A/en unknown
- 2021-02-22 CA CA3168048A patent/CA3168048A1/en active Pending
- 2021-02-22 CN CN202180016068.7A patent/CN115297868B/zh active Active
-
2022
- 2022-03-08 US US17/689,908 patent/US11596685B2/en active Active
- 2022-08-05 ZA ZA2022/08795A patent/ZA202208795B/en unknown
-
2023
- 2023-02-10 US US18/108,248 patent/US11931409B2/en active Active
-
2024
- 2024-02-08 US US18/436,426 patent/US12220456B2/en active Active
-
2025
- 2025-02-07 US US19/048,760 patent/US20250170233A1/en active Pending
- 2025-11-21 AU AU2025271119A patent/AU2025271119A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230241206A1 (en) | 2023-08-03 |
| US11931409B2 (en) | 2024-03-19 |
| AU2021224990B2 (en) | 2025-08-28 |
| JP2023514594A (ja) | 2023-04-06 |
| US11596685B2 (en) | 2023-03-07 |
| ZA202208795B (en) | 2023-11-29 |
| WO2021168405A1 (en) | 2021-08-26 |
| EP4106770A4 (en) | 2024-05-15 |
| KR20250114450A (ko) | 2025-07-29 |
| EP4106770A1 (en) | 2022-12-28 |
| AU2025271119A1 (en) | 2025-12-18 |
| US20240252618A1 (en) | 2024-08-01 |
| MX2022010084A (es) | 2022-12-07 |
| US20220202932A1 (en) | 2022-06-30 |
| KR20220144831A (ko) | 2022-10-27 |
| KR102838785B1 (ko) | 2025-07-28 |
| AU2021224990A1 (en) | 2022-09-15 |
| JP7539723B2 (ja) | 2024-08-26 |
| US12220456B2 (en) | 2025-02-11 |
| CN115297868B (zh) | 2024-04-12 |
| US20250170233A1 (en) | 2025-05-29 |
| CN115297868A (zh) | 2022-11-04 |
| CA3168048A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295724A (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| Galli et al. | Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy | |
| US11865159B2 (en) | Therapeutic RNA | |
| Deckers et al. | Engineering cytokine therapeutics | |
| Di Franco et al. | Role of type I and II interferons in colorectal cancer and melanoma | |
| Rosenberg | Immunotherapy and gene therapy of cancer | |
| Abdolvahab et al. | Interferons: role in cancer therapy | |
| Bommareddy et al. | Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival | |
| TWI850282B (zh) | 用於治療癌症之質體建構體和使用方法 | |
| US11103555B2 (en) | Compositions and methods for reducing tumor cell growth at a site of solid tumor excision | |
| ES2622958T3 (es) | ARNip frente a Cbl-b combinado con citocinas e interferones en el tratamiento de cáncer | |
| Gordy et al. | Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model | |
| US20170260246A1 (en) | Carcinoma homing peptide (chp), its analogs, and methods of using | |
| RU2020112990A (ru) | Композиции и процессы для направленной доставки, экспрессии и модуляции кодирующих рибонуклеиновых кислот в ткани | |
| CN118695868A (zh) | 包含il-10的双细胞因子融合蛋白与过继细胞疗法或双特异性t细胞衔接器用于治疗癌症 | |
| Rafiq et al. | Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects | |
| EP4448016A2 (en) | Dual cytokine fusion proteins comprising multi-subunit cytokines | |
| Jin et al. | Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells | |
| Prodi et al. | Tumor-homing antibody-cytokine fusions for cancer therapy | |
| JP2021506320A5 (https=) | ||
| CN118715239A (zh) | 包含多亚基细胞因子的双细胞因子融合蛋白 | |
| US20230277624A1 (en) | Methods of determining responsiveness to cancer immunotherapy | |
| Mihich | Immunity and Cancer Therapy: Present Status and Future Projections 1 | |
| Liu et al. | Solubility-enhanced gMYL6 fused with a hexa-lysine tag promotes the cytotoxicity of human NK cells | |
| US20250115928A1 (en) | Recombinant Orthopox Viral Vector Encoding Immunostimulatory Proteins for Cancer Treatment |